AJAX Search

search:
joomla slideshow with caption

Representing the PRECLINICAL Portfolio of Mediso in North America

Mediso has a long history in the design, and manufacturing of high-end clinical and life science multi-modality in vivo molecular imaging systems. After 15 years of providing transformative clinical systems, Mediso preclinical systems were introduced in 2006 to address the need for more powerful and quantifiable in vivo imaging for research.

Mediso USA was founded to support all North American preclinical business, service, applications, and training. The flagship of the Mediso preclinical line, nanoScan Family, offers a state-of-the-art platform for small animal PET/SPECT/CT/MR imaging.

The ultimate in preclinical versatility and robust high-end imaging subsystems are based on a common hardware and software platform. Highlighting the versatility of the nanoScan family are the integrated bi-mode combinations of PET/CT, PET/MRI(3T), PET/MRI(1T), SPECT/CT, SPECT/MRI(1T) and the exclusive tri-mode SPECT/CT/PET. Whether your institution is adding a standalone nanoScan modality, precision integrated bi-mode or tri-mode system your investment is secure with a clear modality upgrade path and access to the latest developments for current and future research applications.

Performance is enhanced by efficient workflow. All nanoScan systems include the MultiCell small-animal handling systemsensuring efficient animal preparation, consistent anesthesia delivery, temperature control, and physiology monitoring. Acquisition, reconstruction, and analysis are streamlined by the Mediso-developed operators console consisting of the latest hardware, processors, and intuitive yet powerful software solutions:

Twitter

PRESS RELEASES

Tulane National Primate Research Center receives the 100th Mediso preclinical PET system with installation of the MultiScan Large FOV Extreme Resolution (LFER150) PET/CT

Covington, LA and Boston, MA, October 2, 2018 /PRNewswire/  With the successful installation of the 100th Mediso multi-modality preclinical PET system, the Tulane National Primate Research Center (TNPRC), division of the Tulane University, has become the fourth site in North America to install the MultiScan LFER150 PET/CT preclinical imager.

Huntsman Cancer Institute becomes the first US installation of the nanoScan 3 Tesla PET/MRI

Salt Lake City, UT and Boston, MA, October 2, 2018 /PRNewswire/  The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake City, UT, has become the first site in the US to install the nanoScan PET/MRI 3T preclinical in vivo imaging system. This is the 10th installation of the nanoScan MRI 3T worldwide.

Mediso USA Reaches Milestone With 10th Site of Preclinical nanoScan Imaging Systems

Boston, MA, September 28, 2015 /PRNewswire/  Mediso USA is proud to announce the tenth site of integrated preclinical multimodality imagers of the nanoScan Family in North America, at the preeminent Cold Spring Harbor Laboratory (CSHL).

Huntsman Cancer Institute Becomes the First Mediso Preclinical Imaging Center of Excellence in North America

Salt Lake City, Utah and Boston, MA, September 21, 2015 /PRNewswire/ The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI), part of the University of Utah Health Care system in Salt Lake City, UT, has become the first site in North America to be designated as a Center of Excellence for Preclinical Imaging by Mediso Ltd. and its affiliate company Mediso USA.

EVENTS

EANM 2019
Oct 12 - 16, 2019

WMIC 2019
Sept 4 - 7, 2019

ASP 2019
Aug 21 - 24, 2019

SNMMI 2019
Jun 22 - 25, 2019

LATEST BLOGS

Huntsman Cancer Institute Becomes the First Mediso Preclinical Imaging Center of Excellence in North America

nanoScan SPECT/CT and PET/MRISalt Lake City, Utah and Boston, MA, September 21, 2015 /PRNewswire/

The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI), part of the University of Utah Health Care system in Salt Lake City, UT, has become the first site in North America to be designated as a Center of Excellence for Preclinical Imaging by Mediso Ltd. and its affiliate company Mediso USA. 

Two multi-modality nanoScan in vivo preclinical imaging systems have been installed at HCI: a nanoScan PET/MRI, combining positron emission tomography (PET) and magnetic resonance imaging (MRI) techniques in one integrated system, and a nanoScan SPECT/CT, combining single photon emission tomography (SPECT) and x-ray computed tomography (CT) in one combined system. Both systems seamlessly integrate four imaging modalities without any compromise in image quality, performance and ease of use.

According to Jeffrey Yap, Ph.D., Associate Director of the Center for Quantitative Cancer Imaging at Huntsman Cancer Institute and Research Associate Professor in the Department of Radiology at the University of Utah, "This combination of scanners provides a wide range of options for anatomical, functional, and molecular imaging, including the ability to perform imaging of animals in a single session with four different modalities that are spatially co-registered."

"HCI has an outstanding ranking in the field of cancer research. This is further emphasized by the fact that HCI has been recently awarded Comprehensive Cancer Center status by the National Cancer Institute (NCI). We are proud to receive the possibility to support the focus of HCI scientists to create safer and more effective treatments for the patients," say Illes Muller, Managing Partner of Mediso USA. "HCI researchers have decades of combined clinical and preclinical multi-modality imaging experience. HCI provides a unique combination with the possibility to perform quantitative preclinical imaging covering four modalities - PET, SPECT, MRI and CT. The researchers are able to select any combination of the modalities to interrogate a wide range of biological questions by using the common building blocks developed by Mediso, including the Nucline acquisition framework and the MultiCell animal handling and monitoring system."